Healthcare

INOVIO Receives $71 Million Contract From U.S. Department of Defense

CELLECTRA® 3PSP is designed to deliver INO-4800 directly into the skin, where the vaccine prompts the body's immune system to…

5 years ago

On the treatment of Covid-19

Based on the available scientific evidence and current clinical experience, the SPR Collaboration recommends that physicians and authorities consider the…

5 years ago

FDA approves Ready-to-Use Ephedrine Injection, Emerphed™

Nexus Pharmaceuticals, Inc. Announces Approval of Emerphed™ (ephedrine sulfate) Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10…

5 years ago

AURA™ adds Protein/Non Protein Identification to Horizon®

Aura revolutionizes biologic stability analysis, enabling simple protein and non-protein aggregate identification in formulation development and analytical testing

5 years ago

COVID-19 Testing with 72 Hour or Less Turnaround Time

TCA/GENETWORx is building capability to perform 870,000 tests per day or 26 million per month. In order to meet demand,…

5 years ago

First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial

The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and…

5 years ago

Hepion Pharmaceuticals’ CRV431 Demonstrates Efficacy in Kidney Fibrosis

CRV431 has exerted antifibrotic activity in a number of in vitro and in vivo studies conducted by independent research laboratories

5 years ago

Opdivo® Approved for the Treatment of Advanced Esophageal Squamous Cell Carcinoma

FDA Approved Opdivo demonstrated superior overall survival benefit compared to docetaxel or paclitaxel in ESCC Patients

5 years ago

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test…

5 years ago

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia

5 years ago

This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.

Read More